Product
CIML NK
1 clinical trial
4 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
Myeloproliferative NeoplasmIndication
Juvenile Myelomonocytic LeukemiaClinical trial
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationStatus: , Estimated PCD: 2024-12-01